News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immune Response BioPharma Posts 1st Half 2013 Results


8/12/2013 9:23:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRLog (Press Release) - Aug. 11, 2013 - NEW YORK -- Immune Response BioPharma, Inc., Today Posts First Half 2013 Results and provides a business update for the drug discovery pipeline and partnerships for both NeuroVax for MS & Remune HIV/AIDS Vaccine. IRBP is currently in discussions with several potential partners & will select the best partner to help the company reach its goals of bringing its pipeline to market with the first Multiple Sclerosis Vaccine NeuroVax & HIV/AIDS Vaccine Remune.

First Half 2013 Highlights:

- Executed Two CDA's with Potential Partners

- NeuroVax CDA Executed for Partnering with Pharmaceutical potential partner

- REMUNE CDA Executed for Partnering with Big Pharma for Commercialization Partnership

- Initiated Remune Commercialization Plans

- Initiated Plans to submit BLA's for Remune with EMA, MCAZ, MCC & Thai FDA

- IRBP Selected The American Stock Trust & Transfer Company as Transfer Agent of Record for its Stock

2nd Half 2013 Guidance:

- Secure Partners for Remune Commercialization & NeuroVax co-development, Discussions continue with potential partners

- Submit Responses to FDA for Orphan Designation of NeuroVax for MS & Remune pediatric indications

- Begin Manufacturing Planning for REMUNE with a Ramp up & Stock Piling of REMUNE once partnership secured

- Prepare for BLA submissions with the FDA, EMA, MCAZ, MCC of South Africa, FDA Thai, & BLA Emergency Filings once partnership is secured.

- First Year REMUNE Revenues Estimated North of $1 Billion World Wide upon securing a partner & successful Regulatory Filing Approvals along with Manufacturing & Stock Piling of the vaccine

- REMUNE Pricing $75-150 in Africa and Thailand & impoverished nations

- Initiate IR103 REMUNEX Remune + Amplivax Phase III Clinical Study Planning

"IRBP has had a strong first half of 2013 with fruitful discussions with potential partners for NeuroVax and Remune our two flagship vaccines for MS and HIV/AIDS. We executed two CDA's in this first half of this year one for NeuroVax and one for Remune with two different potential partners. Remune is the only viable and safe HIV/AIDS vaccine the world has and those infected with the disease would benefit greatly from the vaccine & give their immune systems a break from the HAART drugs. Looking forward IRBP will be successful either partnering or going it alone as we will be first to market with the first HIV/AIDS & MS vaccines" IRBP CEO Mr. Buswell.

Immune Response BioPharma, Inc. Maybe Found on the World Wide Web @ www.immuneresponse.net

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES